M
Markus Essler
Researcher at University Hospital Bonn
Publications - 123
Citations - 4144
Markus Essler is an academic researcher from University Hospital Bonn. The author has contributed to research in topics: Prostate cancer & Radionuclide therapy. The author has an hindex of 30, co-authored 123 publications receiving 3159 citations.
Papers
More filters
Journal ArticleDOI
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Kambiz Rahbar,Hojjat Ahmadzadehfar,Clemens Kratochwil,Uwe Haberkorn,Michael Schäfers,Markus Essler,Richard P. Baum,Harshad R. Kulkarni,Matthias Schmidt,Alexander Drzezga,Peter Bartenstein,Andreas Pfestroff,Markus Luster,Ulf Lützen,Marlies Marx,Vikas Prasad,Winfried Brenner,Alexander Heinzel,Felix M. Mottaghy,Juri Ruf,Philipp T. Meyer,Martin Heuschkel,Maria Eveslage,Martin Bögemann,Wolfgang P. Fendler,Bernd J. Krause +25 more
TL;DR: The present retrospective multicenter study of 177Lu-PSMA-617 RLT demonstrates favorable safety and high efficacy exceeding those of other third-line systemic therapies in mCRPC patients.
Journal ArticleDOI
Early side effects and first results of radioligand therapy with 177 Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study
Hojjat Ahmadzadehfar,Kambiz Rahbar,Stefan Kürpig,Martin Bögemann,Michael Claesener,Elisabeth Eppard,Florian C. Gärtner,Sebastian Rogenhofer,Michael Schäfers,Markus Essler +9 more
TL;DR: The initial results indicate that RLT with Lu-PSMA is safe and seems to have low early side-effect profile.
Journal ArticleDOI
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Hojjat Ahmadzadehfar,Elisabeth Eppard,Stefan Kürpig,Rolf Fimmers,Anna Yordanova,Carl Diedrich Schlenkhoff,Florian C. Gärtner,Sebastian Rogenhofer,Markus Essler +8 more
TL;DR: It is confirmed that Lu-PSMA is a safe treatment option for metastatic PC patients and has a low toxicity profile and a positive response to therapy in terms of decline in PSA occurs in about 70% of patients.
Journal ArticleDOI
Theranostics in nuclear medicine practice.
Anna Yordanova,Elisabeth Eppard,Stefan Kürpig,Ralph A. Bundschuh,Stefan Schönberger,Maria A. Gonzalez-Carmona,Georg Feldmann,Hojjat Ahmadzadehfar,Markus Essler +8 more
TL;DR: The aim of this review was to provide a summary of background knowledge and current applications, and to identify the advantages of targeted therapies and imaging in nuclear medicine practices.
Journal ArticleDOI
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.
Hojjat Ahmadzadehfar,Simone Wegen,Anna Yordanova,Rolf Fimmers,Stefan Kürpig,Elisabeth Eppard,Xiao Wei,Carl Diedrich Schlenkhoff,Stefan Hauser,Markus Essler +9 more
TL;DR: Patients with a positive response to RLT, regardless of the rate of decline, had a significantly longer median OS, and there was a significant difference in median OS between responders and non-responders for a change in PSA after the third cycle compared to baseline PSA.